Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIFIC-8
2023-506891-28-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Jan 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab + domvanalimab with Durvalumab + placebo (2 arms). Primary endpoint: Progression-free survival in participants with PD-L1 tumor cell expression at least 50%. Planned start Jan 2024; status: authorised.
02
Drugs
durvalumabdomvanalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-506891-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506891-28-00.